EASYER (EpiAccess SYstem Registry) A Post Market Observational Registry

EpiEP, Inc.36 enrolled

Overview

The objective of the Registry is to provide post market clinical outcome and potential health economics data and confirm the continued safety of the EpiAccess system.

The Registry will be a prospective non-randomized single-arm trial of up to 150 patients enrolled in up to ten (10) centers in the United States. The overall duration of the registry is estimated to be 18 months per site. For the patients the registry duration will be from the time of procedure until discharge from the hospital, estimated to be approximately four (4) days. Prior to enrollment, patients will be evaluated on the basis of the latest available data to establish eligibility. Eligible patients will be considered enrolled in the registry after written informed consent is obtained. As EpiAccess is only used for the access portion of the procedure, the safety performance and effectiveness endpoints are acute from the time of needle insertion until pericardial sac access is achieved. Follow up clinical examinations will be performed according to institutional standard of care. No special tests are required for this device.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Arrhythmias, Cardiac

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient is 18 years of age or older * Pericardial access is clinically indicated * Patient is willing and able to provide written informed consent Exclusion Criteria: * Patients who have any condition which contraindicates pericardial access or who have any condition specified in the Contraindications section of the Instructions for Use. This includes: * Previous cardiac surgery or myocardial infarctions resulting in pericardial fibrosis * Congenital absence of a pericardium * Absence of a free epicardial space * Patients with active infection * History of chronic pericarditis * Patient requiring anti-arrhythmic drug therapy for the treatment of ventricular arrhythmia * Patient not in normal sinus rhythm * Presence of thrombus in the left atrium * Coagulopathy * Known allergy to contrast media

Locations (3)

Vivek Reddy

New York, New York, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Texas Cardiac Arrhythmia

Austin, Texas, United States

Outcomes

Primary Outcomes

Number of Participants with Adverse Events as Measure of Safety

Time frame: Up to 4 days post procedure (or until time of discharge)

Secondary Outcomes

Health Economics

Number of Participants with Extended Hospital Stay as a Measure of Health Economic Value

Time frame: Up to 4 days post procedure (or until time of discharge)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.